A citation-based method for searching scientific literature

Ying Gong, Roel G J Klein Wolterink, Jianxiang Wang, Gerard M J Bos, Wilfred T V Germeraad. J Hematol Oncol 2021
Times Cited: 5







List of co-cited articles
63 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Treatment of patients with advanced cancer with the natural killer cell line NK-92.
Torsten Tonn, Dirk Schwabe, Hans G Klingemann, Sven Becker, Ruth Esser, Ulrike Koehl, Meinolf Suttorp, Erhard Seifried, Oliver G Ottmann, Gesine Bug. Cytotherapy 2013
255
80

Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies.
Keerthana Shankar, Christian M Capitini, Krishanu Saha. Stem Cell Res Ther 2020
23
60

Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.
Rizwan Romee, Maximillian Rosario, Melissa M Berrien-Elliott, Julia A Wagner, Brea A Jewell, Timothy Schappe, Jeffrey W Leong, Sara Abdel-Latif, Stephanie E Schneider, Sarah Willey,[...]. Sci Transl Med 2016
341
60

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
Enli Liu, David Marin, Pinaki Banerjee, Homer A Macapinlac, Philip Thompson, Rafet Basar, Lucila Nassif Kerbauy, Bethany Overman, Peter Thall, Mecit Kaplan,[...]. N Engl J Med 2020
483
60

First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.
Xiaowen Tang, Lin Yang, Zheng Li, Ansel P Nalin, Haiping Dai, Ting Xu, Jia Yin, Fengtao You, Mingqing Zhu, Wenhong Shen,[...]. Am J Cancer Res 2018
146
60


Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity.
Ye Li, David L Hermanson, Branden S Moriarity, Dan S Kaufman. Cell Stem Cell 2018
296
60

Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors.
Julia D Suerth, Michael A Morgan, Stephan Kloess, Dirk Heckl, Christine Neudörfl, Christine S Falk, Ulrike Koehl, Axel Schambach. J Mol Med (Berl) 2016
43
60

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.
Jeffrey S Miller, Yvette Soignier, Angela Panoskaltsis-Mortari, Sarah A McNearney, Gong H Yun, Susan K Fautsch, David McKenna, Chap Le, Todd E Defor, Linda J Burns,[...]. Blood 2005
60

Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia.
Michael Boyiadzis, Mounzer Agha, Robert L Redner, Alison Sehgal, Annie Im, Jing-Zhou Hou, Rafic Farah, Kathleen A Dorritie, Anastasios Raptis, Seah H Lim,[...]. Cytotherapy 2017
78
60

2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
Yingxi Xu, Qian Liu, Mengjun Zhong, Zhenzhen Wang, Zhaoqi Chen, Yu Zhang, Haiyan Xing, Zheng Tian, Kejing Tang, Xiaolong Liao,[...]. J Hematol Oncol 2019
39
40

Generating natural killer cells for adoptive transfer: expanding horizons.
Soumyadipta Kundu, Mark Gurney, Michael O'Dwyer. Cytotherapy 2021
5
40

Human NK cells: surface receptors, inhibitory checkpoints, and translational applications.
Simona Sivori, Paola Vacca, Genny Del Zotto, Enrico Munari, Maria Cristina Mingari, Lorenzo Moretta. Cell Mol Immunol 2019
124
40

A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy.
Emily J Pomeroy, John T Hunzeker, Mitchell G Kluesner, Walker S Lahr, Branden A Smeester, Margaret R Crosby, Cara-Lin Lonetree, Kenta Yamamoto, Laura Bendzick, Jeffrey S Miller,[...]. Mol Ther 2020
39
40

Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.
Lin Xiao, Dongzhi Cen, Haining Gan, Yan Sun, Nanqi Huang, Hanzhen Xiong, Qiongmei Jin, Liqun Su, Xuejuan Liu, Kejian Wang,[...]. Mol Ther 2019
62
40

Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation.
Anna Capsomidis, Gabriel Benthall, Heleen H Van Acker, Jonathan Fisher, Anne M Kramer, Zarah Abeln, Yvonne Majani, Talia Gileadi, Rebecca Wallace, Kenth Gustafsson,[...]. Mol Ther 2018
81
40

Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting.
Antonia Rotolo, Valentina S Caputo, Monika Holubova, Nicoleta Baxan, Olivier Dubois, Mohammed Suhail Chaudhry, Xiaolin Xiao, Katerina Goudevenou, David S Pitcher, Kyriaki Petevi,[...]. Cancer Cell 2018
49
40

PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Kellsye P Fabian, Michelle R Padget, Renee N Donahue, Kristen Solocinski, Yvette Robbins, Clint T Allen, John H Lee, Shahrooz Rabizadeh, Patrick Soon-Shiong, Jeffrey Schlom,[...]. J Immunother Cancer 2020
24
40

Cytotoxicity of Donor Natural Killer Cells to Allo-Reactive T Cells Are Related With Acute Graft-vs.-Host-Disease Following Allogeneic Stem Cell Transplantation.
Lixia Sheng, Qitian Mu, Xiaoqing Wu, Shujun Yang, Huiling Zhu, Jiaping Wang, Yanli Lai, Hao Wu, Ye Sun, Yongxian Hu,[...]. Front Immunol 2020
5
40

Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia.
Meir Rozenbaum, Amilia Meir, Yarden Aharony, Orit Itzhaki, Jacob Schachter, Ilan Bank, Elad Jacoby, Michal J Besser. Front Immunol 2020
30
40

Are natural killer cells superior CAR drivers?
Hans Klingemann. Oncoimmunology 2014
132
40

High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
Stephan Müller, Tobias Bexte, Veronika Gebel, Franziska Kalensee, Eva Stolzenberg, Jessica Hartmann, Ulrike Koehl, Axel Schambach, Winfried S Wels, Ute Modlich,[...]. Front Immunol 2020
27
40

A robust platform for expansion and genome editing of primary human natural killer cells.
Rih-Sheng Huang, Min-Chi Lai, Hsin-An Shih, Steven Lin. J Exp Med 2021
7
40

Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.
Isabella Monia Montagner, Alessandro Penna, Giulio Fracasso, Debora Carpanese, Anna Dalla Pietà, Vito Barbieri, Gaia Zuccolotto, Antonio Rosato. Cells 2020
24
40

A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells.
Yu-Hsiang Chang, John Connolly, Noriko Shimasaki, Kousaku Mimura, Koji Kono, Dario Campana. Cancer Res 2013
183
40

Driving CARs on the uneven road of antigen heterogeneity in solid tumors.
Nan Chen, Xiaoyu Li, Navin K Chintala, Zachary E Tano, Prasad S Adusumilli. Curr Opin Immunol 2018
39
40

CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma.
Guangna Liu, Wei Rui, Hongli Zheng, Daosheng Huang, Fei Yu, Yuewei Zhang, Jiahong Dong, Xueqiang Zhao, Xin Lin. Eur J Immunol 2020
39
40

Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer.
Bihui Cao, Manting Liu, Lu Wang, Baoxia Liang, Yunfei Feng, Xiaopei Chen, Yuanyuan Shi, Jinling Zhang, Xiaodie Ye, Yu Tian,[...]. Biochem Biophys Res Commun 2020
18
40

Engineering NK Cells for CAR Therapy-Recent Advances in Gene Transfer Methodology.
Paula Schmidt, Martin J Raftery, Gabriele Pecher. Front Immunol 2021
11
40

DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy.
Katrin Töpfer, Marc Cartellieri, Susanne Michen, Ralf Wiedemuth, Nadja Müller, Dirk Lindemann, Michael Bachmann, Monika Füssel, Gabriele Schackert, Achim Temme. J Immunol 2015
103
40

Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication.
Christopher C Kloss, Jihyun Lee, Aaron Zhang, Fang Chen, Jan Joseph Melenhorst, Simon F Lacey, Marcela V Maus, Joseph A Fraietta, Yangbing Zhao, Carl H June. Mol Ther 2018
196
40

Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D.
Zhongjuan Wang, Linghua Guo, Yuan Song, Yinsheng Zhang, Dandan Lin, Bo Hu, Yu Mei, Dedy Sandikin, Haiyan Liu. Cancer Immunol Immunother 2017
30
40

Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.
Nadja Müller, Susanne Michen, Stefanie Tietze, Katrin Töpfer, Alexander Schulte, Katrin Lamszus, Marc Schmitz, Gabriele Schackert, Ira Pastan, Achim Temme. J Immunother 2015
94
40


CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.
Michael C Burger, Congcong Zhang, Patrick N Harter, Annette Romanski, Florian Strassheimer, Christian Senft, Torsten Tonn, Joachim P Steinbach, Winfried S Wels. Front Immunol 2019
65
40

Cancer immunotherapy with γδ T cells: many paths ahead of us.
Dieter Kabelitz, Ruben Serrano, Léonce Kouakanou, Christian Peters, Shirin Kalyan. Cell Mol Immunol 2020
37
40

Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy.
Yuan Hu, Zhi-Gang Tian, Cai Zhang. Acta Pharmacol Sin 2018
76
40


Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells.
May Daher, Rafet Basar, Elif Gokdemir, Natalia Baran, Nadima Uprety, Ana Karen Nunez Cortes, Mayela Mendt, Lucila Nassif Kerbauy, Pinaki P Banerjee, Mayra Shanley,[...]. Blood 2021
44
40

Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.
K H Chen, M Wada, K G Pinz, H Liu, K-W Lin, A Jares, A E Firor, X Shuai, H Salman, M Golightly,[...]. Leukemia 2017
79
40

Cytokine activation induces human memory-like NK cells.
Rizwan Romee, Stephanie E Schneider, Jeffrey W Leong, Julie M Chase, Catherine R Keppel, Ryan P Sullivan, Megan A Cooper, Todd A Fehniger. Blood 2012
286
40

Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications.
Natalia Lapteva, April G Durett, Jiali Sun, Lisa A Rollins, Leslie L Huye, Jian Fang, Varada Dandekar, Zhuyong Mei, Kimberley Jackson, Juan Vera,[...]. Cytotherapy 2012
121
40

Expansion of highly cytotoxic human natural killer cells for cancer cell therapy.
Hiroyuki Fujisaki, Harumi Kakuda, Noriko Shimasaki, Chihaya Imai, Jing Ma, Timothy Lockey, Paul Eldridge, Wing H Leung, Dario Campana. Cancer Res 2009
360
40

Rosuvastatin Enhances VSV-G Lentiviral Transduction of NK Cells via Upregulation of the Low-Density Lipoprotein Receptor.
Ying Gong, Roel G J Klein Wolterink, Ian Janssen, Arjan J Groot, Gerard M J Bos, Wilfred T V Germeraad. Mol Ther Methods Clin Dev 2020
10
40

Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.
E Liu, Y Tong, G Dotti, H Shaim, B Savoldo, M Mukherjee, J Orange, X Wan, X Lu, A Reynolds,[...]. Leukemia 2018
260
40

Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92.
G Maki, H G Klingemann, J A Martinson, Y K Tam. J Hematother Stem Cell Res 2001
147
40

Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells.
Cecele J Denman, Vladimir V Senyukov, Srinivas S Somanchi, Prasad V Phatarpekar, Lisa M Kopp, Jennifer L Johnson, Harjeet Singh, Lenka Hurton, Sourindra N Maiti, M Helen Huls,[...]. PLoS One 2012
309
40

Efficient and Robust NK-Cell Transduction With Baboon Envelope Pseudotyped Lentivector.
Aurelien B L Colamartino, William Lemieux, Panojot Bifsha, Simon Nicoletti, Nitin Chakravarti, Joaquín Sanz, Hugo Roméro, Silvia Selleri, Kathie Béland, Mélanie Guiot,[...]. Front Immunol 2019
31
40

Natural Killer Cells: Development, Maturation, and Clinical Utilization.
Alex M Abel, Chao Yang, Monica S Thakar, Subramaniam Malarkannan. Front Immunol 2018
266
40

Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.
Nina Shah, Li Li, Jessica McCarty, Indreshpal Kaur, Eric Yvon, Hila Shaim, Muharrem Muftuoglu, Enli Liu, Robert Z Orlowski, Laurence Cooper,[...]. Br J Haematol 2017
80
40


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.